Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction Insights From PARAGON-HF

被引:284
|
作者
McMurray, John J., V [1 ]
Jackson, Alice M. [1 ]
Lam, Carolyn S. P. [2 ,3 ,4 ,5 ]
Redfield, Margaret M. [6 ]
Anand, Inder S. [7 ]
Ge, Junbo [8 ]
Lefkowitz, Marty P. [9 ]
Maggioni, Aldo P. [10 ]
Martinez, Felipe [11 ]
Packer, Milton [12 ]
Pfeffer, Marc A. [13 ]
Pieske, Burkert [14 ]
Rizkala, Adel R. [9 ]
Sabarwal, Shalini, V [9 ]
Shah, Amil M. [13 ]
Shah, Sanjiv J. [15 ]
Shi, Victor C. [9 ]
van Veldhuisen, Dirk J. [4 ]
Zannad, Faiez [16 ,17 ]
Zile, Michael R. [18 ,19 ]
Cikes, Maja [20 ,21 ]
Goncalvesova, Eva [22 ]
Katova, Tzvetana [23 ]
Kosztin, Anamaria [24 ]
Lelonek, Malgorzata [25 ]
Sweitzer, Nancy [26 ]
Vardeny, Orly [27 ]
Claggett, Brian [13 ]
Jhund, Pardeep S. [1 ]
Solomon, Scott D. [13 ]
机构
[1] Univ Glasgow, BHF Cardiovasc Res Ctr, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland
[2] Natl Heart Ctr Singapore, Singapore, Singapore
[3] Duke Natl Univ Singapore, Singapore, Singapore
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
[5] George Inst Global Hlth, Newtown, Tas, Australia
[6] Mayo Clin, Rochester, MN USA
[7] Univ Minnesota, Minneapolis, MN USA
[8] Shanghai Inst Cardiovasc Dis, Shanghai, Peoples R China
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Natl Assoc Hosp Cardiologists Res Ctr, Florence, Italy
[11] Natl Univ Cordoba, Cordoba, Argentina
[12] Baylor Univ, Med Ctr, Dallas, TX USA
[13] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA
[14] German Ctr Cardiovasc Res, Partner Site Berlin, Dept Internal Med & Cardiol, Berlin, Germany
[15] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA
[16] INSERM, Ctr Invest Clin 1433, Nancy, France
[17] Univ Lorraine, Ctr Hosp Reg & Univ, Nancy, France
[18] Med Univ South Carolina, Charleston, SC 29425 USA
[19] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA
[20] Univ Zagreb, Dept Cardiovasc Dis, Sch Med, Zagreb, Croatia
[21] Univ Hosp Ctr Zagreb, Zagreb, Croatia
[22] Natl Cardiovasc Inst, Dept Heart Failure Transplantat, Bratislava, Slovakia
[23] Natl Cardiol Hosp, Clin Cardiol, Sofia, Bulgaria
[24] Semmelweis Univ, Heart & Vasc Ctr, Budapest, Hungary
[25] Med Univ Lodz, Dept Noninvas Cardiol, Lodz, Poland
[26] Univ Arizona Sarver Heart, Tucson, AZ USA
[27] Univ Minnesota, Minneapolis VA Ctr Care Delivery & Outcomes Res, Minneapolis, MN USA
关键词
heart failure; hospitalization; neprilysin; women; NEPRILYSIN INHIBITION; SEX-DIFFERENCES; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; DYSFUNCTION; AGE;
D O I
10.1161/CIRCULATIONAHA.119.044491
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Unlike heart failure with reduced ejection fraction, there is no approved treatment for heart failure with preserved ejection fraction, the predominant phenotype in women. Therefore, there is a greater heart failure therapeutic deficit in women compared with men. METHODS: In a prespecified subgroup analysis, we examined outcomes according to sex in the PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction), which compared sacubitril-valsartan and valsartan in patients with heart failure with preserved ejection fraction. The primary outcome was a composite of first and recurrent hospitalizations for heart failure and death from cardiovascular causes. We also report secondary efficacy and safety outcomes. RESULTS: Overall, 2479 women (51.7%) and 2317 men (48.3%) were randomized. Women were older and had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels than men. For the primary outcome, the rate ratio for sacubitril-valsartan versus valsartan was 0.73 (95% CI, 0.59-0.90) in women and 1.03 (95% CI, 0.84-1.25) in men (P interaction = 0.017). The benefit from sacubitril-valsartan was attributable to reduction in heart failure hospitalization. The improvement in New York Heart Association class and renal function with sacubitril-valsartan was similar in women and men, whereas the improvement in Kansas City Cardiomyopathy Questionnaire clinical summary score was less in women than in men. The difference in adverse events between sacubitril-valsartan and valsartan was similar in women and men. CONCLUSIONS: As compared with valsartan, sacubitril-valsartan seemed to reduce the risk of heart failure hospitalization more in women than in men. Whereas the possible sex-related modification of the effect of treatment has several potential explanations, the present study does not provide a definite mechanistic basis for this finding.
引用
收藏
页码:338 / 351
页数:14
相关论文
共 50 条
  • [1] Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF"
    Wu, Kai
    Zhao, Song
    [J]. CIRCULATION, 2020, 142 (01) : E3 - E4
  • [2] Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF"
    Jackson, Alice M.
    Jhund, Pardeep S.
    Solomon, Scott D.
    McMurray, John J. V.
    [J]. CIRCULATION, 2020, 142 (01) : E5 - E6
  • [3] The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
    Gronda, Edoardo
    Vanoli, Emilio
    Iacoviello, Massimo
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0L) : L77 - L81
  • [4] Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF
    Peikert, Alexander
    Vaduganathan, Muthiah
    Mc Causland, Finnian
    Claggett, Brian L.
    Chatur, Safia
    Packer, Milton
    Pfeffer, Marc A.
    Zannad, Faiez
    Lefkowitz, Martin P.
    Pieske, Burkert
    Duengen, Hans-Dirk
    McMurray, John J. V.
    Solomon, Scott D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (05) : 794 - 803
  • [5] Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial
    Ostrominski, John
    Claggett, B.
    Packer, M.
    Pfeffer, M.
    Lam, C.
    Zile, M.
    Desai, A.
    Jhund, P.
    Lefkowitz, M.
    Mcmurray, J.
    Solomon, S.
    Vaduganathan, M.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 119 - 119
  • [6] Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
    Ostrominski, John W.
    Claggett, Brian L.
    Packer, Milton
    Pfeffer, Marc A.
    Lam, Carolyn S. P.
    Zile, Michael R.
    Desai, Akshay S.
    Jhund, Pardeep S.
    Lefkowitz, Martin
    Mcmurray, John J. V.
    Solomon, Scott D.
    Vaduganathan, Muthiah
    [J]. JOURNAL OF CARDIAC FAILURE, 2023, 29 (11) : 1494 - 1503
  • [7] EFFECT OF SACUBITRIL/VALSARTAN ON SERUM LIPIDS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF
    Selvaraj, Senthil
    Claggett, Brian
    Packer, Milton
    Zannad, Faiez
    Ananda, Inderjit
    Pieske, Burkert
    Shi, Victor
    Lefkowitz, Martin
    McMurray, John
    Solomon, Scott
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 556 - 556
  • [8] Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction:PARAGON-HF
    Selvaraj, Senthil
    Claggett, Brian L.
    Pfeffer, Marc A.
    Desai, Akshay S.
    Mc Causland, Finnian R.
    McGrath, Martina M.
    Anand, Inder S.
    van Veldhuisen, Dirk J.
    Kober, Lars
    Janssens, Stefan
    Cleland, John G. F.
    Pieske, Burkert
    Rouleau, Jean L.
    Zile, Michael R.
    Shi, Victor C.
    Lefkowitz, Martin P.
    McMurray, John J. V.
    Solomon, Scott D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (11) : 2093 - 2101
  • [9] EFFECTS OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN ON RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF
    Peikert, Alexander
    Vaduganathan, Muthiah
    McCausland, Finnian
    Claggett, Brian
    Chatur, Safia
    Packer, Milton
    Pfeffer, Marc A.
    Zannad, Faiez
    Lefkowitz, Martin
    Pieske, Burkert Mathias
    Dungen, Hans-Dirk
    McMurray, John J. V.
    Solomon, Scott D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 308 - 308
  • [10] Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial
    Lund, Lars H.
    Savarese, Gianluigi
    Venkateshvaran, Ashwin
    Benson, Lina
    Lundberg, Anna
    Donal, Erwan
    Daubert, Jean-Claude
    Oger, Emmanuel
    Linde, Cecilia
    Hage, Camilla
    [J]. ESC HEART FAILURE, 2022, 9 (01): : 164 - 177